The clinical course and long-term outcome of primary focal segmental glomerulosclerosis in Chinese adults

Clinical Nephrology

Volumn 80, Issue 2, 2013, Pages 130-139

  Tang, Xi ^a   Xu, Feng ^a   Chen, Dong Mei ^a   Zeng, Cai Hong ^a   Liu, Zhi Hong ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

End stage renal disease; Focal segmental glomerulosclerosis; Renal survival; Tripterygium wilfordii

Indexed keywords

PREDNISONE; TRIPTERYGIUM WILFORDII EXTRACT;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; DISEASE COURSE; FEMALE; FOCAL GLOMERULOSCLEROSIS; FOLLOW UP; HUMAN; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NEPHROTIC SYNDROME; PROTEINURIA; REMISSION; RETROSPECTIVE STUDY; SURVIVAL RATE; TRIPTERYGIUM WILFORDII;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; FEMALE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; MALE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84881502988     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CN107607     Document Type: Article

References (44)

1. Korbet SM. Clinical picture and outcome of primary focal segmental glomerulosclerosis. Nephrol Dial Transplant. 1999; 14 (Suppl 3): 68-73.
2. Li LS, Liu ZH. Epidemiologic data of renal diseases from a single unit in China: analysis based on 13,519 renal biopsies. Kidney Int. 2004; 66: 920-923.
3. Kitiyakara C, Kopp JB, Eggers P. Trends in the epidemiology of focal segmental glomerulosclerosis. Semin Nephrol. 2003; 23: 172-182.
4. Kitiyakara C, Eggers P, Kopp JB. Twenty-oneyear trend in ESRD due to focal segmental glomerulosclerosis in the United States. Am J Kidney Dis. 2004; 44: 815-825.
5. Cattran DC. Are all patients with idiopathic focal segmental glomerulosclerosis (FSGS) created equal? Nephrol Dial Transplant. 1998; 13: 1107- 1109.
6. Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC; Toronto Glomerulonephritis Registry Group. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol. 2005; 16: 1061-1068.
7. D'Agati VD, Fogo AB, Bruijn JA, Jennette JC. Pathologic classification of focal segmental glomerulosclerosis: a working proposal. Am J Kidney Dis. 2004; 43: 368-382.
8. Waldman M, Crew RJ, Valeri A, Busch J, Stokes B, Markowitz G, D'Agati V, Appel G. Adult minimal- change disease: clinical characteristics, treatment, and outcomes. Clin J Am Soc Nephrol. 2007; 2: 445-453.
9. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol. 2006; 17: 2937-2944.
10. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A; Acute Kidney Injury Network. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care. 2007; 11: R31.
11. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, Maxwell DR, Kunis CL; North America Nephrotic Syndrome Study Group. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. Kidney Int. 1999; 56: 2220-2226.
12. Goldbach-Mansky R, Wilson M, Fleischmann R, Olsen N, Silverfield J, Kempf P, Kivitz A, Sherrer Y, Pucino F, Csako G, Costello R, Pham TH, Snyder C, Van der Heijde D, Tao X, Wesley R, Lipsky PE. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. Ann Intern Med. 2009; 151: 229-240.
13. Peng A, Gu Y, Lin SY. Herbal treatment for renal diseases. Ann Acad Med Singapore. 2005; 34: 44-51.
14. Nada R, Kharbanda JK, Bhatti A, Minz RW, Sakhuja V, Joshi K. Primary focal segmental glomerulosclerosis in adults: is the Indian cohort different?. Nephrol Dial Transplant. 2009; 24: 3701-3707.
15. Zhang Q, Zeng C, Cheng Z, Xie K, Zhang J, Liu Z. Primary focal segmental glomerulosclerosis in nephrotic patients: common complications and risk factors. J Nephrol. 2012; 25: 679-688.
16. Van Timmeren MM, Bakker SJ, Vaidya VS, Bailly V, Schuurs TA, Damman J, Stegeman CA, Bonventre JV, van Goor H. Tubular kidney injury molecule- 1 in protein-overload nephropathy. Am J Physiol Renal Physiol. 2006; 291: F456-F464.
17. Burton CJ, Combe C, Walls J, Harris KP. Secretion of chemokines and cytokines by human tubular epithelial cells in response to proteins. Nephrol Dial Transplant. 1999; 14: 2628-2633.
18. Gulati S, Elhence R, Kher V, Sharma RK, Jain M, Gupta A, Gupta RK. Early versus late-onset idiopathic focal segmental glomerulosclerosis. Pediatr Nephrol. 2000; 14: 960-964.
19. Jafry N, Ahmed E, Mubarak M, Kazi J, Akhter F. Raised serum creatinine at presentation does not adversely affect steroid response in primary focal segmental glomerulosclerosis in adults. Nephrol Dial Transplant. 2012; 27: 1101-1106.
20. Shiiki H, Nishino T, Uyama H, Kimura T, Nishimoto K, Iwano M, Kanauchi M, Fujii Y, Dohi K. Clinical and morphological predictors of renal outcome in adult patients with focal and segmental glomerulosclerosis (FSGS). Clin Nephrol. 1996; 46: 362-368.
21. Ponticelli C, Villa M, Banfi G, Cesana B, Pozzi C, Pani A, Passerini P, Farina M, Grassi C, Baroli A. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis. 1999; 34: 618-625.
22. Chen YZ, Gao Q, Zhao XZ, Chen XM, Zhang F, Chen J, Xu CG, Sun LL, Mei CL. Meta-analysis of Tripterygium wilfordii Hook F in the immunosuppressive treatment of IgA nephropathy. Intern Med. 2010; 49: 2049-2055.
23. Xia Y, Mao J, Chen Y, Wang D, Cao L, Yao S, Fu H, Du L, Liu A. Clinical outcomes in children with Henoch-Schönlein purpura nephritis grade IIIa or IIIb. Pediatr Nephrol. 2011; 26: 1083-1088.
24. Sharma M, Li JZ, Sharma R, Artero M, Ge X, McCarthy ET, Wang HY, Savin V. Inhibitory effect of Tripterygium wilfordii multiglycoside on increased glomerular albumin permeability in vitro. Nephrol Dial Transplant. 1997; 12: 2064-2068.
25. Zheng CX, Chen ZH, Zeng CH, Qin WS, Li LS, Liu ZH. Triptolide protects podocytes from puromycin aminonucleoside induced injury in vivo and in vitro. Kidney Int. 2008; 74: 596-612.
26. Chen ZH, Qin WS, Zeng CH, Zheng CX, Hong YM, Lu YZ, Li LS, Liu ZH. Triptolide reduces proteinuria in experimental membranous nephropathy and protects against C5b-9-induced podocyte injury in vitro. Kidney Int. 2010; 77: 974-988.
27. Gao Q, Shen W, Qin W, Zheng C, Zhang M, Zeng C, Wang S, Wang J, Zhu X, Liu Z. Treatment of db/ db diabetic mice with triptolide: a novel therapy for diabetic nephropathy. Nephrol Dial Transplant. 2010; 25: 3539-3547.
28. Xu G, Tu W, Jiang D, Xu C. Tripterygium wilfordii Hook F treatment for idiopathic refractory nephrotic syndrome in adults: a meta-analysis. Nephron Clin Pract. 2009; 111: c223-c228.
29. Yang M, Huang J, Pan HZ, Jin J. Triptolide overcomes dexamethasone resistance and enhanced PS-341-induced apoptosis via PI3k/Akt/NF-kappaB pathways in human multiple myeloma cells. Int J Mol Med. 2008; 22: 489-496.
30. Yang M, Shen JK, Huang J, Du HP, Ma QL, Jin J. Interleukin-6-independent expression of glucocorticoid receptor is upregulated by triptolide in multiple myeloma. Leuk Lymphoma. 2009; 50: 802-808.
31. Cameron JS, Turner DR, Ogg CS, Chantler C, Williams DG. The long-term prognosis of patients with focal segmental glomerulosclerosis. Clin Nephrol. 1978; 10: 213-218.
32. Korbet SM, Schwartz MM, Lewis EJ. The prognosis of focal segmental glomerular sclerosis of adulthood. Medicine (Baltimore). 1986; 65: 304-311.
33. Deegens JK, Steenbergen EJ, Borm GF, Wetzels JF. Pathological variants of focal segmental glomerulosclerosis in an adult Dutch population - epidemiology and outcome. Nephrol Dial Transplant. 2008; 23: 186-192.
34. Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol. 2004; 15: 2169-2177.
35. Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis. 1995; 25: 534-542.
36. Brown CB, Cameron JS, Turner DR, Chantler C, Ogg CS, Williams DG, Bewick M. Focal segmental glomerulosclerosis with rapid decline in renal function ("malignant FSGS"). Clin Nephrol. 1978; 10: 51-61.
37. Korbet SM. Treatment of primary focal segmental glomerulosclerosis. Kidney Int. 2002; 62: 2301-2310.
38. Alexopoulos E, Stangou M, Papagianni A, Pantzaki A, Papadimitriou M. Factors influencing the course and the response to treatment in primary focal segmental glomerulosclerosis. Nephrol Dial Transplant. 2000; 15: 1348-1356.
39. Stirling CM, Mathieson P, Boulton-Jones JM, Feehally J, Jayne D, Murray HM, Adu D. Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units. QJM. 2005; 98: 443-449.
40. Schwartz MM, Evans J, Bain R, Korbet SM. Focal segmental glomerulosclerosis: prognostic implications of the cellular lesion. J Am Soc Nephrol. 1999; 10: 1900-1907.
41. Chitalia VC, Wells JE, Robson RA, Searle M, Lynn KL. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. Kidney Int. 1999; 56: 2236-2242.
42. Thomas DB, Franceschini N, Hogan SL, Ten Holder S, Jennette CE, Falk RJ, Jennette JC. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int. 2006; 69: 920-926.
43. Arias LF, Franco-Alzate C, Rojas SL. Tip variant of focal segmental glomerulosclerosis: outcome and comparison to 'not otherwise specified' variant. Nephrol Dial Transplant. 2011; 26: 2215-2221.
44. Schwartz MM, Korbet SM, Rydell J, Borok R, Genchi R. Primary focal segmental glomerular sclerosis in adults: prognostic value of histologic variants. Am J Kidney Dis. 1995; 25: 845-852.